ArticleLupus science & medicine2026
Old marker, new face: anti-RNP as a sentinel of coronary and peripheral endothelial dysfunction in systemic lupus erythematosus.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the association between anti-ribonucleoprotein (anti-RNP) antibodies and endothelial dysfunction (ED) in patients with SLE and their ability to predict early ED manifestations, both coronary and peripherally.
methodsA cross-sectional study was conducted at a tertiary hospital involving 70 patients with SLE meeting American College of Rheumatology (ACR)/Systemic Lupus International Collaborating Clinics (SLICC) criteria. All study participants underwent a full clinical and laboratory evaluation, including testing for Cardiovascular Diseases serum anti-RNP antibodies. Conventional transthoracic 2-dimensional echocardiography, tissue Doppler imaging and a transthoracic dobutamine stress echocardiography to assess coronary microvasculature by measuring coronary flow velocity reserve (CFVR). Peripheral microvascular morphology was evaluated via nailfold dermoscopy. The primary outcome measures were the mean CFVR values and the presence of dermoscopic abnormalities (capillary drop-out, tortuosity and density) in relation to anti-RNP titres.
resultsIn 70 patients with SLE, those with high disease activity (n=45) exhibited significantly impaired cardiac function compared with low-activity patients (n=25), showing lower ejection fraction (EF) and CFVR, alongside higher Wall Motion Score Index (p<0.05). Anti-RNP levels correlated positively with Systemic Lupus Erythematosus Disease Activity Index (SLEDAI, r=0.653, p<0.001), erythrocyte sedimentation rate, proteinuria and Raynaud's phenomenon. Significant negative correlations existed between anti-RNP and stress EF (r=-0.33), CFVR (r=-0.30), C3 and C4 (p<0.05). Furthermore, elevated anti-RNP levels were significantly associated with clinical manifestations such as myositis and avascular necrosis, as well as dermoscopic microvascular changes, including microhaemorrhage and capillary dropouts (p<0.05).
conclusionsHigh anti-RNP titres are significantly associated with subclinical coronary microvascular impairment and peripheral capillary architectural changes in SLE. These results suggest that anti-RNP acts as a sentinel marker for early ED, providing potential for improved cardiovascular risk stratification independent of traditional risk factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.